Palvella Therapeutics Inc/$PVLA

13:30
09:10
04:45
00:25
20:00
1D1W1MYTD1Y5YMAX

About Palvella Therapeutics Inc

Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.

Ticker

$PVLA
Sector
Health Care
Primary listing
NASDAQ

Industry

Biotechnology
Headquarters
Wayne, United States

Employees

14
Website
palvellatx.com

PVLA Metrics

BasicAdvanced
$404M
-
-$5.05
-
-

Bulls say / Bears say

Palvella Therapeutics completed a merger with Pieris Pharmaceuticals and secured a $78.9 million private placement, resulting in a strong cash position of approximately $80 million, expected to fund operations into the second half of 2027. (globenewswire.com)
The company's lead product candidate, QTORIN™ 3.9% rapamycin anhydrous gel, is advancing into a Phase 3 SELVA clinical trial for microcystic lymphatic malformations, with data expected in early 2026, potentially addressing a significant unmet medical need. (investing.com)
Analysts have initiated coverage with positive ratings: Scotiabank assigned a 'Sector Outperform' rating with a $50 price target, and TD Cowen issued a 'Buy' rating with a $44 price target, indicating strong confidence in the company's growth prospects. (nasdaq.com, marketbeat.com)
Despite a strong cash position, Palvella reported a net loss of $17.4 million for the year ended December 31, 2024, highlighting ongoing financial challenges. (stocktitan.net)
The company's lead product, QTORIN™ rapamycin, is still in clinical trials, and any delays or unfavorable results could significantly impact the company's valuation and future prospects. (investing.com)
Palvella operates in the highly competitive biopharmaceutical sector, and the success of its products is contingent upon regulatory approvals and market acceptance, which are uncertain and can be time-consuming. (globenewswire.com)
Data summarised monthly by Lightyear AI. Last updated on 16 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $PVLA

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs